The American Journal of Surgery
Volume 197, Issue 1 , Pages 43-48 , January 2009

A single nucleotide polymorphism in the Mdm2 promoter and risk of sepsis

Received 30 May 2007 ,Revised 6 December 2007

References 

  1. Villar J, Maca-Meyer N, Perez-Mendez L, et al. Bench-to-bedside review: understanding genetic predisposition to sepsis. Crit Care. 2004;8:180–189
  2. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–1256
  3. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest. 2003;124:1103–1115
  4. Arcaroli J, Fessler MB, Abraham E. Genetic polymorphisms and sepsis. Shock. 2005;24:300–312
  5. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–1197
  6. Yamanishi Y, Boyle DL, Pinkoski MJ, et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol. 2002;160:123–130
  7. Hotchkiss RS, Tinsley KW, Hui JJ, et al. p53-dependent and -independent pathways of apoptotic cell death in sepsis. J Immunol. 2000;164:3675–3680
  8. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9:338–342
  9. Simelyte E, Rosengren S, Boyle DL, et al. Regulation of arthritis by p53: critical role of adaptive immunity. Arthritis Rheum. 2005;52:1876–1884
  10. Power CP, Wang JH, Manning B, et al. Bacterial lipoprotein delays apoptosis in human neutrophils through inhibition of caspase-3 activity: regulatory roles for CD14 and TLR-2. J Immunol. 2004;173:5229–5237
  11. Hotchkiss RS, Coopersmith CM, Karl IE. Prevention of lymphocyte apoptosis–a potential treatment of sepsis?. Clin Infect Dis. 2005;41(suppl 7):S465–S469
  12. Momand J, Wu HH, Dasgupta G. MDM2–master regulator of the p53 tumor suppressor protein. Gene. 2000;242:15–29
  13. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res. 2003;1:993–1000
  14. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602
  15. Arva NC, Gopen TR, Talbott KE, et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells. J Biol Chem. 2005;280:26776–26787
  16. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001–1008
  17. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure (On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine). Intensive Care Med. 1996;22:707–710
  18. Salvo I, de Cian W, Musicco M, et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med. 1995;21(suppl. 2):S244–S249
  19. Brown PE, McClave SA, Hoy NW, et al. The Acute Physiology and Chronic Health Evaluation II classification system is a valid marker for physiologic stress in the critically ill patient. Crit Care Med. 1993;21:363–367
  20. Copson ER, White HE, Blaydes JP, et al. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer. 2006;6:80;http://www.biomedcentral.com/1471-2407/6/80
  21. Ottonello L, Cutolo M, Frumento G, et al. Synovial fluid from patients with rheumatoid arthritis inhibits neutrophil apoptosis: role of adenosine and proinflammatory cytokines. Rheumatology (Oxford). 2002;41:1249–1260
  22. Ina K, Kusugami K, Hosokawa T, et al. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease. J Gastroenterol Hepatol. 1999;14:46–53
  23. Akahoshi T, Nagaoka T, Namai R, et al. Prevention of neutrophil apoptosis by monosodium urate crystals. Rheumatol Int. 1997;16:231–235
  24. Giamarellos-Bourboulis EJ, Routsi C, Plachouras D, et al. Early apoptosis of blood monocytes in the septic host: is it a mechanism of protection in the event of septic shock?. Crit Care. 2006;10:R76;http://ccforum.com/content/10/3/R76
  25. Goodman JE, Hofseth LJ, Hussain SP, et al. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen. 2004;44:3–9
  26. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032–1037
  27. Hudson JD, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999;190:1375–1382
  28. Mitchell RA, Liao H, Chesney J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002;99:345–350
  29. Hodge DR, Peng B, Cherry JC, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 2005;65:4673–4682
  30. Diodato KM, Schwacha MG, Bland KI, et al. Gender differences in the inflammatory response and survival following haemorrhage and subsequent sepsis. MD Cytokine. 2001;14:162–169
  31. van Eijk LT, Dorresteijn MJ, Smits P, et al. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med. 2007;35:1464–1469
  32. Coyle SM CS, Lowry SF. Gender influences in vivo human responses to endotoxin. Shock. 2006;26:538–543
  33. Atwal GS, Bond GL, Metsuyanim S, et al. Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci U S A. 2007;104:4524–4529
  34. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66:5104–5110
  35. Phelps M, Darley M, Primrose JN, et al. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res. 2003;63:2616–2623
  36. Qi JS, Yuan Y, Desai-Yajnik V, et al. Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol Cell Biol. 1999;19:864–872
  37. Gou DY, Su W, Shao YC, et al. Euthyroid sick syndrome in trauma patients with severe inflammatory response syndrome. Chin J Traumatol. 2006;9:115–117
  38. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170–1175

PII: S0002-9610(08)00262-6

doi: 10.1016/j.amjsurg.2007.12.049

The American Journal of Surgery
Volume 197, Issue 1 , Pages 43-48 , January 2009

Article Tools

* Image Usage & Resolution